Key messages
Background
Methods
Patients
Pre-MPZ (n = 16) | Post–MPZ (n = 16) | P value* | |
---|---|---|---|
Clinical manifestations at diagnosis, n (%) | Asthma 16 (100), general 10 (62.5), cutaneous 8 (50.0), ENT 5 (31.3), chest 8 (50.0), cardiomyopathy 3 (18.8), abdominal 1 (6.3), neuropathy 8 (50.0), ANCA positive status 5 (31.3), biopsy findings 12 (75) | ||
Male/female/age at MPZ introduction | 7/9/61.5 [53.3–70.5] | ||
Disease duration (months) at MPZ introduction | 54 [22–144] | ||
Treatment history, n (%) | CS pulse 2 (12.5), high-dose CS 14 (87.5), low-dose CS 2 (12.5), IVCY 9 (56.3), IVIG 6 (37.5), RTX 1 (6.3), MTX 6 (37.5), AZ 12 (75.0), TAC 1 (6.3) | ||
Relapsing/refractory/remission, n (%) | 4 (25.0)/11 (68.7)/1 (6.3) | 10 (62.5)/6 (37.5)/0 (0) | ND |
Concomitant CS dose (PSL mg/day) | 8.0 [5.0–11.5] | 6.5 [2.6–10.0] | 0.2012 |
Concomitant CS < 4 mg/day (PSL), n (%) | 3 (18.8) | 5 (31.3) | 0.1573 |
Concomitant immunosuppressant, n (%) | AZ 6 (37.5), MTX 5 (31.3), TAC 1 (6.3) | AZ 6 (37.5), MTX 4 (25.0), TAC 1 (6.3) | |
Without immunosuppressant, n (%) | 6 (37.5) | 7 (43.8) | 0.3173 |
BVAS | 0 [0–2.0] | 1.0 [0–3.8] | 0.1084 |
BVAS > 0, n (%) | 4 (25.0) | 8 (50.0) | 0.3173 |
BVAS items | Asthma 2 (12.5), sinonasal 2 (12.5), chest 1 (6.3) | Asthma 6 (37.5), general 1 (6.3), cutaneous 2 (12.5), sinonasal 2 (12.5), chest 3 (18.8), | |
VDI | 3.5 [3.0–4.8] | 4.0 [3.0–5.8] | 0.5577 |
VDI items | Chronic bronchial asthma 16 (100), chronic respiratory failure 1 (6.3), abnormal respiratory function 7 (43.8), old myocardial infarction 2 (12.5), cardiomyopathy 2 (12.5), low vision 1 (6.3), chronic sinusitis 6 (37.5), deafness 3 (18.8), peripheral neuropathy 8 (50.0), diabetes 4 (25), hypertension 4 (25), osteoporosis 5 (31.3), other 3 (18.8) | Chronic bronchial asthma 16 (100), chronic respiratory failure 1 (6.3), abnormal respiratory function 8 (50.0), old myocardial infarction 2 (12.5), cardiomyopathy 2 (12.5), low vision 1 (6.3), chronic sinusitis 7 (43.8), deafness 3 (18.8), peripheral neuropathy 8 (50.0), diabetes 4 (25), hypertension 4 (25), osteoporosis 5 (31.3), other 5 (31.3) | |
ANCA-positive status, n (%) | 0 (0) | 1 (6.3) | ND |
Absolute eosinophil count (/μL) | 178.6 [48.7–370.2] | 183 [60.0–2479] | 0.1591 |
CRP (mg/dL) | 0.06 [0.03–0.09] | 0.09 [0.05–0.24] | 0.0593 |
Clinical measurement
Measurement of serum concentration of IL-5
Statistical analysis
Results
Patient background
Effectiveness of MPZ
Pre-MPZ | Post-MPZ | ||||||||
---|---|---|---|---|---|---|---|---|---|
-12 M | -11 M | -9 M | -6 M | 0 M | 1 M | 3 M | 6 M | 12 M | |
General symptoms | 0 | 0 | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 0 | 1 (6.3%) | 0 |
Cutaneous manifestations | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 1 (6.3%) | 2 (12.5%) | 2 (12.5%) | 0 | 1 (6.3%) | 0 |
ENT manifestations | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 6 (37.5%) | 4 (25.0%) | 3 (18.8%) |
Chest manifestations | 6 (37.5%) | 6 (37.5%) | 8 (50.0%) | 8 (50.0%) | 11 (68.8%) | 5 (31.3%) | 2 (12.5%) | 2 (12.5%) | 2 (12.5%) |
Nervous system manifestations | 7 (45.8%) | 7 (45.8%) | 7 (45.8%) | 8 (50.0%) | 8 (50.0%) | 8 (50.0%) | 7 (43.8%) | 7 (43.8%) | 7 (43.8%) |
Case No. | Pre-MPZ | Post-MPZ | |||||||
---|---|---|---|---|---|---|---|---|---|
− 12 months | − 11 months | − 9 months | − 6 months | 0 months | 1 months | 3 months | 6 months | 12 months | |
1 | 5 mg | 5 mg | 30 mg | 15 mg | 15 mg | 15 mg | 10 mg | 10 mg | 5 mg |
2 | 5 mg | 5 mg | 7.5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg |
3 | 8 mg | 8 mg | 3.5 mg | 2.5 mg | 2.5 mg | 2.5 mg | 2 mg | 2 mg | 1.5 mg |
4 | 12 mg | 12 mg | 12 mg | 12 mg | 12 mg | 10 mg | 8 mg | 9 mg | 4 mg |
5 | 8 mg | 8 mg | 7 mg | 7 mg | 7 mg | 7 mg | 5 mg | 5 mg | 3 mg |
6 | 1 mg | 1 mg | 1 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg |
7 | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg |
8 | 10 mg | 9 mg | 7 mg | 6 mg | 6 mg | 6 mg | 5 mg | 3 mg | 0.5 mg |
9 | 5 mg | 5 mg | 4 mg | 3 mg | 3 mg | 3 mg | 3 mg | 0 mg | 0 mg |
10 | 15 mg | 10 mg | 5 mg | 35 mg | 20 mg | 15 mg | 7.5 mg | 5 mg | 3 mg |
11 | 8 mg | 8 mg | 7 mg | 7 mg | 7 mg | 7 mg | 5 mg | 5 mg | 2 mg |
12 | 20 mg | 15 mg | 10 mg | 10 mg | 10 mg | 10 mg | 7 mg | 5 mg | 2 mg |
13 | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg | 10 mg | 8 mg | 6 mg | 5 mg |
14 | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 5 mg | 3 mg | 3 mg |
15 | 20 mg | 15 mg | 8 mg | 7 mg | 7 mg | 7 mg | 5 mg | 4 mg | 3 mg |
16 | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg | 0 mg |
Case No. | Pre-MPZ | Post-MPZ | |||||||
---|---|---|---|---|---|---|---|---|---|
− 12 months | − 11 months | − 9 months | − 6 months | 0 months | 1 months | 3 months | 6 months | 12 months | |
1 | MTX 8 mg | MTX 8 mg | None | None | None | None | None | None | None |
2 | MTX 8 mg+AZ 125 mg | MTX 8 mg+AZ 125 mg | MTX 8 mg+AZ 125 mg | MTX 8 mg+AZ 125 mg | MTX 8 mg+AZ 125 mg | AZ125 mg | AZ125 mg | AZ125 mg | AZ100 mg |
3 | AZ50 mg | AZ50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg |
4 | None | None | AZ 50 mg | None | None | None | None | MTX 8 mg | MTX 8 mg |
5 | MTX 6 mg+AZ 50 mg | MTX 6 mg+AZ 50 mg | MTX 6 mg+AZ 50 mg | MTX 6 mg+AZ 50 mg | MTX 6 mg+AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg |
6 | MTX 16 mg | MTX 16 mg | MTX 16 mg | MTX 16 mg | MTX 16 mg | MTX 16 mg | MTX 10 mg | MTX 4 mg | None |
7 | None | None | None | None | None | None | None | None | None |
8 | MTX 12 mg | MTX 12 mg | MTX 12 mg | MTX 12 mg | MTX 12 mg | None | None | None | None |
9 | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | None | None | None | None |
10 | None | None | IVCY | None | None | None | None | None | None |
11 | TAC 3 mg | TAC 3 mg | TAC 3 mg | TAC 3 mg | TAC 3 mg | None | None | None | None |
12 | None | None | None | None | None | None | None | None | None |
13 | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg | AZ 50 mg |
14 | None | None | None | None | None | None | None | None | None |
15 | AZ 100 mg | AZ 100 mg | AZ 100 mg | AZ 100 mg | AZ 100 mg | None | None | None | None |
16 | None | None | None | None | None | None | None | None | None |
MPZ retention rate and safety
Case No. | Pre-MPZ | Post-MPZ |
---|---|---|
1 | Bacterial pneumonia (hospitalization) | Bacterial pneumonia (hospitalization) Bacterial species: Moraxella catarrhalis |
2 | None | None |
3 | None | None |
4 | Drug-induced liver injury | None |
5 | Sinusitis surgery, bacterial bronchitis | None |
6 | Bacterial bronchitis, infectious otitis media | None |
7 | None | None |
8 | None | None |
9 | None | None |
10 | None | None |
11 | Bacterial pneumonia (hospitalization) | Bacterial pneumonia (hospitalization) Bacterial species: Pseudomonas aeruginosa |
12 | None | None |
13 | Bacterial pneumonia (hospitalization) | None |
14 | Bacterial bronchitis | None |
15 | Bacterial pneumonia | Bacterial pneumonia |
16 | None | None |